Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate Cancer - Episode 6

Available Genomic Tests for Clinically Localized Prostate Cancer

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

EP. 1: Staging, Grading, and Risk Stratification of Prostate Cancer
EP. 2: Treatment Options for High-Risk, Clinically Localized Prostate Cancer
EP. 3: Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer
EP. 4: The Potential for Overtreatment or Undertreatment of Prostate Cancer
EP. 5: Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing
Now Viewing
EP. 6: Available Genomic Tests for Clinically Localized Prostate Cancer

Related Content:

Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate CancerProstate CancerUroView
Adding pembrolizumab to docetaxel does not significantly improve outcomes in mCRPC
Exciting Prospects for the Future of Localized Prostate Cancer Treatment
Follow-up Considerations for Patients Receiving Focal Therapy